Japan conditionally approves Amchepry (iPS-cell dopamine precursors)

The research record

This is the project's file for this landmark, as written and checked. Sources are listed at the end; anything not yet confirmed is marked "Not yet verified".

Who

Sumitomo Pharma (applicant, marketing) and RACTHERA, a joint venture of Sumitomo Chemical and Sumitomo Pharma that took over the company's regenerative medicine work on 1 February 2025. Cells are made by S-RACMO, another Sumitomo joint venture, at its Suita facility. The science comes from Kyoto University Hospital and CiRA (landmark 300). Who paid for the trial and what licence terms link Kyoto University and Sumitomo are not stated in the sources read.

What happened

• Approval. Manufacturing and marketing approval was granted on 6 March 2026. It is conditional and time-limited: Sumitomo Pharma must run a post-marketing clinical study and surveillance to confirm benefit within the set period. The ministry's committee had found the product approvable on 19 February 2026 (landmark 300 cites the PMDA report for a 7-year period).
• Indication. Improving motor symptoms in people with Parkinson's whose response to existing drugs, including levodopa, is inadequate.
• Evidence behind it. The seven-person Kyoto Phase 1/2 trial published in Nature in April 2025. There was no control group. The company releases give no numbers.
• Designations. Orphan regenerative medicine product designation (December 2025) and Sakigake priority review designation (date not given in the sources read). The marketing application was filed on 5 August 2025.
• Launch. Press reports say it was listed on Japan's national health insurance on 20 May 2026 at about 55 million yen per treatment set, with supply limited to centres in the post-marketing study. Treat the price as unconfirmed.

Why it moved us toward a cure

It shows that regulators will accept replacing lost dopamine neurons as a route to treatment, on small-trial evidence, if the proof comes afterwards. It also sets a precedent for other cell therapies, such as bemdaneprocel in its Phase 3 (landmark 158). It treats symptoms by replacing cells; whether grafts last, or are invaded by the disease, is still open.

Outcome

Advanced. Approved in Japan only. In the US the same cells are in a Phase 1/2 trial (landmark 348); they are not approved there.

Sources

• Sumitomo Pharma / RACTHERA release, 6 March 2026: approval, conditions, joint ventures
• Sumitomo Pharma release, 15 July 2026: indication, orphan designation, post-marketing study under way
• Sumitomo Pharma release, 5 August 2025: filing and Sakigake
• Michael J. Fox Foundation (secondary; the "first" claim)
• Not yet verified: the ministry's (MHLW/PMDA) own approval notice, not reachable by automated reading; the exact Japanese label wording; the length of the conditional period (7 years from a PMDA report and trade press); the 19 February council date (from landmark 300's PMDA source, not re-read); price and launch date (Japanese trade press only); who funded the Kyoto trial and any licence terms.